All 9 /Events 0 /In The News 4 /Press Releases 5

NRG Therapeutics Selects First Development Candidate, NRG5051, and Secures Grant from The Michael J. Fox Foundation for Development of mPTP Inhibitors to Treat Neurodegenerative Diseases

First development candidate selected, NRG5051, with potential…
31 October 2024/by Webadm

NRG Therapeutics launches Series B after $5m boost from Michael J. Fox Foundation

Business Weekly

Read more
31 October 2024/by Webadm

NRG Therapeutics gets grant to test mitochondria-targeting ALS therapy

ALS News Today

Read more
13 September 2024/by Webadm

NRG Therapeutics Awarded Grant Funding from Target ALS to Support the Development of mPTP Inhibitors as Novel Treatments for ALS/MND

Stevenage, UK, 5 August 2024 - NRG Therapeutics, Ltd., an innovative…
5 September 2024/by Webadm

Case Study: Life Sciences – Future50

PwC

Read more
(pdf)
19 October 2023/by Webadm

NRG Therapeutics Appoints Dr Jonathan Savidge as Independent Chair

Stevenage, UK, 26 April 2023 - NRG Therapeutics, Ltd., an innovative…
26 April 2023/by Webadm

NRG Therapeutics Appoints Vad Lazari Ph.D. as Vice President of Biology to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders

Vad Lazari Ph.D., appointed to newly created position of…
19 April 2023/by Webadm

9 neuroscience biotech companies you should know about

Labiotech

Read more
3 April 2023/by Webadm

NRG Therapeutics Announces International Scientific Advisory Board

Stevenage, UK, 30 March 2023 - NRG Therapeutics, Ltd., an innovative…
30 March 2023/by Webadm

NRG Therapeutics: Restoring motor neuron function via mitochondria

BioCentury Read more (behind a paywall)

NRG raises $67M to test mitochondrial pore inhibitor in ALS

BioWorld Read more (behind a paywall)

A UK biotech takes aim at Parkinson’s, ALS by drugging mitochondria

Biopharma Dive Read more

UK’s NRG Powers Up With £50m For Promising Mitochondrial Therapy

SCRIP Read more (behind a paywall)

NRG raises $67 million for a small molecule for Parkinson’s and ALS

c&en Read more

Stevenage, UK based NRG Therapeutics raised a $67M series B today to advance its aim to restore mitochondrial function and slow the progression of neurodegenerative diseases like Parkinson’s and ALS

Biotech TV Watch more

NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND

Oversubscribed £50m Series B led by SV Health Investors’…

Mitochondria: Movers and Shakers – a podcast about life with Parkinson’s

Apple Podcasts Listen more